Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 236

1.

ADCY5-Related Dyskinesia: Improving Clinical Detection of an Evolving Disorder.

Vijiaratnam N, Bhatia KP, Lang AE, Raskind WH, Espay AJ.

Mov Disord Clin Pract. 2019 Aug 19;6(7):512-520. doi: 10.1002/mdc3.12816. eCollection 2019 Sep. Review.

PMID:
31538084
2.

Sex differences by design and outcome in the Safety of Urate Elevation in PD (SURE-PD) trial.

Schwarzschild MA, Macklin EA, Bakshi R, Battacharyya S, Logan R, Espay AJ, Hung AY, Bwala G, Goetz CG, Russell DS, Goudreau JL, Parashos SA, Saint-Hilaire MH, Rudolph A, Hare JM, Curhan GC, Ascherio A; Parkinson Study Group SURE-PD Investigators.

Neurology. 2019 Sep 4. pii: 10.1212/WNL.0000000000008194. doi: 10.1212/WNL.0000000000008194. [Epub ahead of print]

PMID:
31484712
3.

Orthostatic hypotension and dementia incidence: links and implications.

Robertson AD, Udow SJ, Espay AJ, Merola A, Camicioli R, Lang AE, Masellis M.

Neuropsychiatr Dis Treat. 2019 Aug 2;15:2181-2194. doi: 10.2147/NDT.S182123. eCollection 2019.

4.

Dystonia in atypical parkinsonian disorders.

Marsili L, Bologna M, Kojovic M, Berardelli A, Espay AJ, Colosimo C.

Parkinsonism Relat Disord. 2019 Jul 23. pii: S1353-8020(19)30320-7. doi: 10.1016/j.parkreldis.2019.07.030. [Epub ahead of print] Review.

PMID:
31443953
5.

The cerebellar phenotype of Charcot-Marie-Tooth neuropathy type 4C.

Skott H, Muntean-Firanescu C, Samuelsson K, Verrecchia L, Svenningsson P, Malmgren H, Cananau C, Espay AJ, Press R, Solders G, Paucar M.

Cerebellum Ataxias. 2019 Jul 15;6:9. doi: 10.1186/s40673-019-0103-8. eCollection 2019.

6.

Hallucinations, somatic-functional disorders of PD-DLB as expressions of thalamic dysfunction.

Onofrj M, Espay AJ, Bonanni L, Delli Pizzi S, Sensi SL.

Mov Disord. 2019 Aug;34(8):1100-1111. doi: 10.1002/mds.27781. Epub 2019 Jul 15. Review.

PMID:
31307115
7.

The "broken wishbone" splenial sign: A diagnostic hallmark for SPG54 spastic ataxia.

Zaidi SA, Saal HM, Espay AJ, Duker AP.

J Neurol Sci. 2019 Aug 15;403:114-116. doi: 10.1016/j.jns.2019.06.012. Epub 2019 Jun 13. No abstract available.

PMID:
31271950
8.

Orthostatic hypotension and REM sleep behaviour disorder: impact on clinical outcomes in α-synucleinopathies.

Pilotto A, Romagnolo A, Tuazon JA, Vizcarra JA, Marsili L, Zibetti M, Rosso M, Rodriguez-Porcel F, Borroni B, Rizzetti MC, Rossi C, Vizcarra-Escobar D, Molano JR, Lopiano L, Ceravolo R, Masellis M, Espay AJ, Padovani A, Merola A.

J Neurol Neurosurg Psychiatry. 2019 May 29. pii: jnnp-2019-320846. doi: 10.1136/jnnp-2019-320846. [Epub ahead of print] Review.

PMID:
31142660
9.

Functional movement disorders in neurogeriatric inpatients : Underdiagnosed, often comorbid to neurodegenerative disorders and treatable.

Mätzold S, Geritz J, Zeuner KE, Berg D, Paschen S, Hieke J, Sablowsky S, Ortlieb C, Bergmann P, Hofmann W, Espay AJ, Maetzler W.

Z Gerontol Geriatr. 2019 Jul;52(4):324-329. doi: 10.1007/s00391-019-01562-y. Epub 2019 May 28. Review.

PMID:
31139963
10.

Lack of independent mood-enhancing effect for dopaminergic medications in early Parkinson's disease.

Espay AJ, Foster ED, Coffey CS, Uribe L, Caspell-Garcia CJ, Weintraub D; Parkinson's Progression Markers Initiative.

J Neurol Sci. 2019 Jul 15;402:81-85. doi: 10.1016/j.jns.2019.05.009. Epub 2019 May 16.

PMID:
31125734
11.

Hiding in Plain Sight: Functional Neurological Disorders in the News.

Popkirov S, Nicholson TR, Bloem BR, Cock HR, Derry CP, Duncan R, Dworetzky BA, Edwards MJ, Espay AJ, Hallett M, Lang AE, Leach JP, Lehn A, McGonigal A, Morgante F, Perez DL, Reuber M, Richardson MP, Smith P, Stamelou M, Tijssen MAJ, Tinazzi M, Carson AJ, Stone J.

J Neuropsychiatry Clin Neurosci. 2019 May 23:appineuropsych19010025. doi: 10.1176/appi.neuropsych.19010025. [Epub ahead of print]

PMID:
31117907
12.

The Final Nail in the Coffin of Disease Modification for Dopaminergic Therapies: The LEAP Trial.

Espay AJ.

JAMA Neurol. 2019 Jul 1;76(7):747-748. doi: 10.1001/jamaneurol.2019.0974. No abstract available.

PMID:
31058964
13.

Reply to 'Neuropathological progression of clinical Parkinson disease subtypes'.

Espay AJ, Marras C.

Nat Rev Neurol. 2019 Jun;15(6):361-362. doi: 10.1038/s41582-019-0198-9. No abstract available.

PMID:
31048773
14.

Should neurologists diagnose and manage functional neurologic disorders? It is complicated.

Perez DL, Haller AL, Espay AJ.

Neurol Clin Pract. 2019 Apr;9(2):165-167. doi: 10.1212/CPJ.0000000000000573.

PMID:
31041133
15.

Head tremor at disease onset: an ataxic phenotype of cervical dystonia.

Merola A, Dwivedi AK, Shaikh AG, Tareen TK, Da Prat GA, Kauffman MA, Hampf J, Mahajan A, Marsili L, Jankovic J, Comella CL, Berman BD, Perlmutter JS, Jinnah HA, Espay AJ.

J Neurol. 2019 Aug;266(8):1844-1851. doi: 10.1007/s00415-019-09341-w. Epub 2019 Apr 26.

PMID:
31028543
16.

A roadmap for implementation of patient-centered digital outcome measures in Parkinson's disease obtained using mobile health technologies.

Espay AJ, Hausdorff JM, Sánchez-Ferro Á, Klucken J, Merola A, Bonato P, Paul SS, Horak FB, Vizcarra JA, Mestre TA, Reilmann R, Nieuwboer A, Dorsey ER, Rochester L, Bloem BR, Maetzler W; Movement Disorder Society Task Force on Technology.

Mov Disord. 2019 May;34(5):657-663. doi: 10.1002/mds.27671. Epub 2019 Mar 22. Review.

PMID:
30901495
17.

The Parkinson's disease e-diary: Developing a clinical and research tool for the digital age.

Vizcarra JA, Sánchez-Ferro Á, Maetzler W, Marsili L, Zavala L, Lang AE, Martinez-Martin P, Mestre TA, Reilmann R, Hausdorff JM, Dorsey ER, Paul SS, Dexheimer JW, Wissel BD, Fuller RLM, Bonato P, Tan AH, Bloem BR, Kopil C, Daeschler M, Bataille L, Kleiner G, Cedarbaum JM, Klucken J, Merola A, Goetz CG, Stebbins GT, Espay AJ; MDS Technology Task Force and the MDS Rating Scales Program Electronic Development Ad-Hoc Committee.

Mov Disord. 2019 May;34(5):676-681. doi: 10.1002/mds.27673. Epub 2019 Mar 22. No abstract available.

PMID:
30901492
18.

Globular Glial Tauopathy May be Mistaken for Corticobasal Syndrome-Pointers for the Clinician.

Marsili L, Dickson DW, Espay AJ.

Mov Disord Clin Pract. 2018 Jul 19;5(4):439-441. doi: 10.1002/mdc3.12634. eCollection 2018 Jul-Aug. No abstract available.

19.

Clinical Parkinson disease subtyping does not predict pathology.

Espay AJ, Marras C.

Nat Rev Neurol. 2019 Apr;15(4):189-190. doi: 10.1038/s41582-019-0153-9. No abstract available.

PMID:
30787432
20.

Arm Levitation as Initial Manifestation of Creutzfeldt-Jakob Disease: Case Report and Review of the Literature.

Ciarlariello VB, Barsottini OGP, Espay AJ, Pedroso JL.

Tremor Other Hyperkinet Mov (N Y). 2018 Dec 10;8:572. doi: 10.7916/D80C6CGX. eCollection 2018. Review.

21.

OnabotulinumtoxinA and cognitive behavioral therapy in functional dystonia: A pilot randomized clinical trial.

Vizcarra JA, Lopez-Castellanos JR, Dwivedi AK, Schmerler DA, Ries S, Espay AJ.

Parkinsonism Relat Disord. 2019 Jun;63:174-178. doi: 10.1016/j.parkreldis.2019.02.009. Epub 2019 Feb 13.

PMID:
30777651
22.

Holmes Tremor-Like Phenotype in DYT1 Dystonia.

Rodriguez-Quiroga S, Gonzalez-Moron D, Espay AJ, Kauffman MA.

Mov Disord Clin Pract. 2018 Feb 7;5(2):206-208. doi: 10.1002/mdc3.12585. eCollection 2018 Mar-Apr. No abstract available.

23.

Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases.

Espay AJ, Vizcarra JA, Marsili L, Lang AE, Simon DK, Merola A, Josephs KA, Fasano A, Morgante F, Savica R, Greenamyre JT, Cambi F, Yamasaki TR, Tanner CM, Gan-Or Z, Litvan I, Mata IF, Zabetian CP, Brundin P, Fernandez HH, Standaert DG, Kauffman MA, Schwarzschild MA, Sardi SP, Sherer T, Perry G, Leverenz JB.

Neurology. 2019 Feb 12;92(7):329-337. doi: 10.1212/WNL.0000000000006926.

PMID:
30745444
24.

Movement Disorders in Metabolic Disorders.

Pedroso JL, Barsottini OG, Espay AJ.

Curr Neurol Neurosci Rep. 2019 Feb 9;19(2):7. doi: 10.1007/s11910-019-0921-3. Review.

PMID:
30739241
25.

Association of Subthalamic Deep Brain Stimulation With Motor, Functional, and Pharmacologic Outcomes in Patients With Monogenic Parkinson Disease: A Systematic Review and Meta-analysis.

Artusi CA, Dwivedi AK, Romagnolo A, Pal G, Kauffman M, Mata I, Patel D, Vizcarra JA, Duker A, Marsili L, Cheeran B, Woo D, Contarino MF, Verhagen L, Lopiano L, Espay AJ, Fasano A, Merola A.

JAMA Netw Open. 2019 Feb 1;2(2):e187800. doi: 10.1001/jamanetworkopen.2018.7800.

26.

Effect of subthalamic deep brain stimulation on posture in Parkinson's disease: A blind computerized analysis.

Roediger J, Artusi CA, Romagnolo A, Boyne P, Zibetti M, Lopiano L, Espay AJ, Fasano A, Merola A.

Parkinsonism Relat Disord. 2019 May;62:122-127. doi: 10.1016/j.parkreldis.2019.01.003. Epub 2019 Jan 8.

PMID:
30638820
27.
28.

Soft signs in movement disorders: friends or foes?

Fearon C, Espay AJ, Lang AE, Lynch T, Martino D, Morgante F, Quinn NP, Vidailhet M, Fasano A.

J Neurol Neurosurg Psychiatry. 2019 Aug;90(8):961-962. doi: 10.1136/jnnp-2018-318455. Epub 2018 Nov 8. No abstract available.

PMID:
30409889
29.

A Proposed Roadmap for Parkinson's Disease Proof of Concept Clinical Trials Investigating Compounds Targeting Alpha-Synuclein.

Merchant KM, Cedarbaum JM, Brundin P, Dave KD, Eberling J, Espay AJ, Hutten SJ, Javidnia M, Luthman J, Maetzler W, Menalled L, Reimer AN, Stoessl AJ, Weiner DM; and The Michael J. Fox Foundation Alpha Synuclein Clinical Path Working Group.

J Parkinsons Dis. 2019;9(1):31-61. doi: 10.3233/JPD-181471.

30.

Pimavanserin for Parkinson's Disease psychosis: Effects stratified by baseline cognition and use of cognitive-enhancing medications.

Espay AJ, Guskey MT, Norton JC, Coate B, Vizcarra JA, Ballard C, Factor SA, Friedman JH, Lang AE, Larsen NJ, Andersson C, Fredericks D, Weintraub D.

Mov Disord. 2018 Nov;33(11):1769-1776. doi: 10.1002/mds.27488. Epub 2018 Nov 2.

31.

Q&A with Alberto Espay.

Espay AJ.

Mov Disord. 2018 Oct;33(10):1561-1563. doi: 10.1002/mds.27531. No abstract available.

PMID:
30365220
32.

Movement disorders phenomenology in focal motor seizures.

Fasano A, Di Bonaventura C, Bove F, Espay AJ, Morgante F, Fabbrini G, Munhoz RP, Andrade D, Borlot F, Bui E, Di Gennaro G, Iorio R, Katzberg H, Luigetti M, Striano P, Defazio G, Berardelli A.

Parkinsonism Relat Disord. 2019 Apr;61:161-165. doi: 10.1016/j.parkreldis.2018.10.021. Epub 2018 Oct 16.

PMID:
30361137
33.

Levodopa-induced dyskinesia in Parkinson disease: Current and evolving concepts.

Espay AJ, Morgante F, Merola A, Fasano A, Marsili L, Fox SH, Bezard E, Picconi B, Calabresi P, Lang AE.

Ann Neurol. 2018 Dec;84(6):797-811. doi: 10.1002/ana.25364. Epub 2018 Nov 30. Review.

PMID:
30357892
34.

Technology-based assessment of motor and nonmotor phenomena in Parkinson disease.

Merola A, Sturchio A, Hacker S, Serna S, Vizcarra JA, Marsili L, Fasano A, Espay AJ.

Expert Rev Neurother. 2018 Nov;18(11):825-845. doi: 10.1080/14737175.2018.1530593. Epub 2018 Oct 8.

PMID:
30269610
35.

Epileptic chorea: Another window into neural networks?

Gameleira FT, Alúcio KT, de Paiva MLMN, de Lima Carlos KC, de Lima KM, Gameleira MH, Kauffman MA, Espay AJ.

J Neurol Sci. 2018 Nov 15;394:138-140. doi: 10.1016/j.jns.2018.09.009. Epub 2018 Sep 11. No abstract available.

PMID:
30266016
36.

Teaching Video NeuroImages: The signs of dystonic tremor: Tremulous "escanciador".

Sharma J, Macias-Garcia D, Zaidi A, Espay AJ.

Neurology. 2018 Sep 18;91(12):e1204-e1205. doi: 10.1212/WNL.0000000000006215. No abstract available.

PMID:
30224511
37.

Telemedicine in Neurological Disorders: Opportunities and Challenges.

Chirra M, Marsili L, Wattley L, Sokol LL, Keeling E, Maule S, Sobrero G, Artusi CA, Romagnolo A, Zibetti M, Lopiano L, Espay AJ, Obeidat AZ, Merola A.

Telemed J E Health. 2019 Jul;25(7):541-550. doi: 10.1089/tmj.2018.0101. Epub 2018 Aug 23.

PMID:
30136898
38.

Cognition among individuals along a spectrum of increased risk for Parkinson's disease.

Chahine LM, Urbe L, Caspell-Garcia C, Aarsland D, Alcalay R, Barone P, Burn D, Espay AJ, Hamilton JL, Hawkins KA, Lasch S, Leverenz JB, Litvan I, Richard I, Siderowf A, Coffey CS, Simuni T, Weintraub D; Parkinson’s Progression Markers Initiative.

PLoS One. 2018 Aug 20;13(8):e0201964. doi: 10.1371/journal.pone.0201964. eCollection 2018.

39.

Coxa saltans misdiagnosed as functional gait disorder: Two cases.

Gilbert DL, Espay AJ, Wu SW.

Neurology. 2018 Aug 7;91(6):276-277. doi: 10.1212/WNL.0000000000005955. No abstract available.

PMID:
30082438
40.

Reverse blood pressure dipping as marker of dysautonomia in Parkinson disease.

Milazzo V, Di Stefano C, Vallelonga F, Sobrero G, Zibetti M, Romagnolo A, Merola A, Milan A, Espay AJ, Lopiano L, Veglio F, Maule S.

Parkinsonism Relat Disord. 2018 Nov;56:82-87. doi: 10.1016/j.parkreldis.2018.06.032. Epub 2018 Jun 28.

PMID:
30057156
41.

Subthalamic deep brain stimulation and levodopa in Parkinson's disease: a meta-analysis of combined effects.

Vizcarra JA, Situ-Kcomt M, Artusi CA, Duker AP, Lopiano L, Okun MS, Espay AJ, Merola A.

J Neurol. 2019 Feb;266(2):289-297. doi: 10.1007/s00415-018-8936-2. Epub 2018 Jun 16. Review.

PMID:
29909467
42.

Consensus for the measurement of the camptocormia angle in the standing patient.

Margraf NG, Wolke R, Granert O, Berardelli A, Bloem BR, Djaldetti R, Espay AJ, Fasano A, Furusawa Y, Giladi N, Hallett M, Jankovic J, Murata M, Tinazzi M, Volkmann J, Berg D, Deuschl G.

Parkinsonism Relat Disord. 2018 Jul;52:1-5. doi: 10.1016/j.parkreldis.2018.06.013. Epub 2018 Jun 8.

PMID:
29907329
43.

Movement disorders in non-encephalopathic Hashimoto's thyroiditis.

Miranda M, Bustamante ML, Campero M, Wainstein E, Toche P, Espay AJ, Walker RH, Lang AE.

Parkinsonism Relat Disord. 2018 Oct;55:141-142. doi: 10.1016/j.parkreldis.2018.06.008. Epub 2018 Jun 5. No abstract available.

PMID:
29887356
44.

Current Concepts in Diagnosis and Treatment of Functional Neurological Disorders.

Espay AJ, Aybek S, Carson A, Edwards MJ, Goldstein LH, Hallett M, LaFaver K, LaFrance WC Jr, Lang AE, Nicholson T, Nielsen G, Reuber M, Voon V, Stone J, Morgante F.

JAMA Neurol. 2018 Sep 1;75(9):1132-1141. doi: 10.1001/jamaneurol.2018.1264.

PMID:
29868890
45.

Dopaminergic dose adjustment and negative affective symptoms after deep brain stimulation.

Tareen TK, Artusi CA, Rodriguez-Porcel F, Devoto JL, Sheikh H, Mandybur GT, Duker AP, Espay AJ, Merola A.

J Neurol Sci. 2018 Jul 15;390:33-35. doi: 10.1016/j.jns.2018.04.002. Epub 2018 Apr 7. No abstract available.

PMID:
29801902
46.

Post-stroke Movement Disorders: The Clinical, Neuroanatomic, and Demographic Portrait of 284 Published Cases.

Suri R, Rodriguez-Porcel F, Donohue K, Jesse E, Lovera L, Dwivedi AK, Espay AJ.

J Stroke Cerebrovasc Dis. 2018 Sep;27(9):2388-2397. doi: 10.1016/j.jstrokecerebrovasdis.2018.04.028. Epub 2018 May 21. Review.

PMID:
29793802
47.

Parkinson's Patients with Dyskinesia Switched from Immediate Release Amantadine to Open-label ADS-5102.

Isaacson SH, Fahn S, Pahwa R, Tanner CM, Espay AJ, Trenkwalder C, Adler CH, Patni R, Johnson R.

Mov Disord Clin Pract. 2018 Mar-Apr;5(2):183-190. doi: 10.1002/mdc3.12595. Epub 2018 Feb 23.

48.

Diagnostic criteria for camptocormia in Parkinson's disease: A consensus-based proposal.

Fasano A, Geroin C, Berardelli A, Bloem BR, Espay AJ, Hallett M, Lang AE, Tinazzi M.

Parkinsonism Relat Disord. 2018 Aug;53:53-57. doi: 10.1016/j.parkreldis.2018.04.033. Epub 2018 May 8.

PMID:
29759930
49.

Reply to: "Autonomic dysfunction in Parkinson's disease: The hidden game changer?"

Merola A, Romagnolo A, Lopiano L, Espay AJ.

Mov Disord. 2018 Jul;33(6):1028-1029. doi: 10.1002/mds.27421. Epub 2018 May 14. No abstract available.

PMID:
29756304
50.

Video NeuroImages: Head titubation in anti-mGluR1 autoantibody-associated cerebellitis.

Pedroso JL, Dutra LA, Espay AJ, Höftberger R, Barsottini OGP.

Neurology. 2018 Apr 17;90(16):746-747. doi: 10.1212/WNL.0000000000005338. No abstract available.

PMID:
29661893

Supplemental Content

Loading ...
Support Center